Acute cardiac care & resuscitation
Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial
Study context
- Population
- Patients with initial cardiogenic shock complicating acute myocardial infarction (MI) undergoing primary angioplastyplanned, approximately
- Participants
- 550 patients
- Planned comparison
- IV cangrelor vs crushed ticagrelor
- Primary endpoint
- All-cause death, MI or stroke
- Follow-up
- 30 days
Methodological detailsrationale and design, double-blind, placebo-controlled, multicentre, 5 countries, Main secondary endpoints within 1 year: net clinical endpoint (death, MI, urgent revascularisation of infarct-related artery, stroke or BARC major bleeding); CV death, MI, urgent revascularisation or HF; HF; CV death, Platelet reactivity substudy (VASP phosphorylation): periprocedural rate of onset and proportion achieving effective P2Y12 inhibition
- Rationale and design
- Double-blind
- Placebo-controlled
- Multicentre
- 5 countries
- Main secondary endpoints within 1 year: net clinical endpoint (death, MI, urgent revascularisation of infarct-related artery, stroke or BARC major bleeding); CV death, MI, urgent revascularisation or HF; HF; CV death
- Platelet reactivity substudy (VASP phosphorylation): periprocedural rate of onset and proportion achieving effective P2Y12 inhibition
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. EuroIntervention. Published 21 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →